ASTX-295 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase II drugs for Uveal Melanoma have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ASTX-295’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ASTX-295 overview

ASTX-295 is under development for the treatment of advanced metastatic and refractory solid tumors, malignant pleural mesothelioma, uveal melanoma, liposarcoma, dedifferentiated liposarcoma, well differentiated liposarcoma, glioblastoma multiforme and acute myelocytic leukemia (AML, acute myeloblastic leukemia). The drug candidate is administered through oral route and acts by targeting murine double minute 2 (MDM2) and wild-type TP53.

Taiho Pharmaceutical overview

Taiho Pharmaceutical (Taiho), a subsidiary of Otsuka Group, is a global pharmaceutical company primarily engaged in the research, development, and supply of pharmaceutical products. The company’s main activities include the development of innovative drugs, particularly in the areas of oncology and immune-related diseases. Taiho’s major products include a range of prescription drugs, such as Lonsurf and other consumer healthcare products. The company serves a broad customer base, including patients, healthcare professionals, and medical staff, providing solutions for various health conditions and diseases. The company’s products are available worldwide. Taiho operates globally, with business locations in the US, Europe, Asia, and Oceania. Taiho is headquartered in Tokyo, Japan.

For a complete picture of ASTX-295’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.